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ABSTRACT 
Background/Aims  
This study characterized the safety and pharmacologic properties of AVI-005, a novel glycosylated recombinant 
human interferon-α2b produced from the egg whites of chickens transfected with human cDNA.  
Methods  
Sixteen healthy volunteers received single rising doses of AVI-005. A subcutaneous dose of 0.5, 1.66 or 5 
million international units (MIU) was administered. A randomized parallel comparator group of 10 subjects 
received 5 MIU unglycosylated IFN-α2b (Intron A). The pharmacokinetic parameters t1/2, Tmax, Cmax, AUC0-24 
hr, Vd, and clearance were compared between AVI-005 and unglycosylated IFN-α2b.  
Results  
At equipotent doses, AVI-005 generated a larger AUC0-24hr than the control interferon. Pharmacodynamic 
markers of neopterin and β2 microglobulin were similar between the two treatments. These markers 
demonstrated dose dependent increases to AVI-005. Pharmacodynamic measures of mRNA expression of PKR 
and 2’5’ oligoadenylate synthetase demonstrated a response to treatment with AVI-005. Adverse events were 
qualitatively and quantitatively similar in both groups.  
Conclusion 
AVI-005 demonstrates biologic activity and pharmacokinetic properties in humans that support further 
development. 
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INTRODUCTION 
 
The interferons (IFNs) are immunomodulatory cytokines with antiviral and antitumor properties. (1).  IFN-α is 
produced by leucocytes in response to viral infections. (2)  Interferon -α2b (IFN-α2b) is an alpha interferon 
subtype used in the treatment of chronic hepatitis B and C, malignant melanoma, follicular (non-Hodgkin's) 
lymphoma, AIDS-related Kaposi's sarcoma, condylomata acuminata, and hairy cell leukemia.  In humans, the 
native form of IFN-α2b consists of a single polypeptide chain of 165 amino acids with O-linked glycosylation 
at residue threonine-106.  There are presently two FDA-approved recombinant IFN-α2b products, Intron A, and 
PEG-Intron (Schering-Plough, Kenilworth, NJ).  Intron A is bacterial-derived non-glycosylated protein with an 
amino acid sequence identical to the natural IFN-α2b.  PEG-Intron is comprised of the same underlying 
polypeptide chain linked to polyethylene glycol (PEG).  This synthetic glycosylation provides improved 
efficacy with once-weekly administration. (3)   
 
The current standard of care for the treatment of hepatitis C virus (HCV) infections is an interferon plus 
ribavirin. (4)  Approximately 55% of patients with the most prevalent form of HCV do not respond to currently 
available interferon therapeutics.  According to the World Health Organization, 200 million people, or 3% of 
the world's population, are infected with HCV with 170 million chronic carriers globally at risk of developing 
liver cirrhosis and hepatocellular carcinoma. (5)  The Third National Health and Nutrition Examination Survey 
(NHANES III) found that 1.8 percent of Americans (3.9 million) have been infected with HCV. (6)  An 
additional 400 million people worldwide are chronically infected with hepatitis B virus (HBV). (7)  Thirty 
percent of HBV patients who tolerate interferon therapy have successful response. (8)  Despite proven efficacy, 
the high cost of producing IFN-α2b by present methods places this treatment out of reach of the large majority 
of patients worldwide who suffer from these interferon-remediable infections. 
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AVI-005 is a transgenic human IFN-α2b produced by purification of chicken egg whites from hens transfected 
with human IFN-α2b cDNA.  The AVI-005 manufacturing process involves 1) construction of a vector carrying 
the human IFN-α2b transgene, 2) insertion of IFN-α2b transgene into the chicken genome using embryo 
transduction technique, 3) screening of hatched birds to identify birds carrying the human transgene 4) breeding 
and characterization of transgenic birds to identify a founder (G1), 5) characterization of the G1 founder and its 
subsequent generations to confirm stable transmission of the IFN-α2b transgene through multiple generations 
and 6) harvesting and purification of the AVI-005 protein from the egg white.  An advantage of this process is 
the ability to generate relatively large amounts of transgenic protein, which may translate into reduced 
production costs of recombinant human IFN-α2b.  The amino acid structure of AVI-005 matches that of the 
native human IFN α2b.  AVI-005 differs from the existing commercially available IFN-α2b products in that the 
threonine residue at position 106 is glycosylated with carbohydrate chains making it chemically identical to 
endogenous human IFN-α2b.   
 
The goal of this first-in-human study was to characterize the safety, tolerability, pharmacokinetics and 
pharmacodynamics of AVI-005 in healthy human volunteers upon intramuscular administration of rising single 
doses, and to assess similarity to the existing commercially available IFN α2b product Intron A, henceforth 
described as “control interferon”. 
 
PATIENTS AND METHODS 
 
Subjects 
Twenty eight healthy volunteers were enrolled in this study.  Informed consent was obtained from each subject 
prior to any study procedures.  The study protocol conforms to the ethical guidelines of the Declaration of 
Helsinki as reflected in approval by the Institutional Review Board of Thomas Jefferson University.  Subjects 
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were deemed to be in good health on the basis of medical history, physical examination, laboratory values, and 
electrocardiograms (ECG).  No subjects used prescription or over-the counter medications 2 weeks prior to 
study start.  The mean age of the subjects was 31 years (range 19-49).  Twenty-two (79%) of the subjects were 
male.  Seventeen (61%) subjects were white, 8 (28%) were black and 3 (11%) were Hispanic. 
 
 
Study Design 
This was an open label, single rising dose study of intramuscular AVI-005 in healthy subjects.  At the highest 
dose level, subjects were randomized to either AVI-005 or an equivalent dose of control interferon in a parallel 
design.  The treatment groups were as follows: 1) 0.50 million units equivalent of AVI-005 (4 subjects), 2) 1.66 
million units equivalent of AVI-005 (4 subjects), and 3) 5.00 million units equivalent of AVI-005 or control 
interferon (10 subjects in each treatment arm).  The selection of the dose was based on preclinical data in 
primates employing AVI-005 doses of 0.13, 0.9, and 4.7 µg/kg which correspond, respectively, to 0.3, 2.2, and 
11 times the human doses used in the current trial.  The equivalency of AVI-005 doses to control interferon 
doses was determined by a bioactivity assay calibrated with one used for control interferon using a defined 
reference standard. 
 
Each subject received a thorough physical exam, clinical laboratory safety assessment (hematology, 
electrolytes, liver function tests, and urinalysis) and ECG during screening.  Female subjects had negative 
serum pregnancy test during screening and a negative urine pregnancy test the morning of study drug 
administration.  Study subjects received a single intramuscular injection in the left buttock followed by 
pharmacokinetic and pharmacodynamic sampling.  ECG’s were performed at screening, within 1 hour of 
dosing, at 8 hours, and 3 and 30 days post study drug administration.  Injection sites were observed for signs of 
irritation or inflammation.   
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Pharmacokinetics 
Blood for AVI-005 pharmacokinetics was drawn at baseline and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72, 
96, 120 and 144 hours after drug administration.  Subjects receiving control interferon had blood drawn for 
pharmacokinetics at predose; and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours after drug administration.  
Serum levels of AVI-005 and control interferon were determined using an interferon alpha specific ELISA.  A 
96-well plate was coated with an interferon alpha specific monoclonal antibody (Chemicon, Temcula, CA).  
Following blocking of the non-coated surface area with bovine serum albumin (Sigma, St. Louis, MO), the 
appropriate sample or standard was added.  Captured interferon-α2b was detected with a secondary polyclonal 
anti-IFN alpha antibody which was indicated by a third alkaline phosphatase-conjugated antibody.  The amount 
of IFN-α2b in a tested sample was indicated by the increase in the optical density at 450 nm after addition of 
alkaline phosphatase substrate.  Concentration was calculated by interpolation using a standard curve generated 
with either AVI-005 internal standard or control interferon.  
 
Pharmacodynamics 
Pharmacodynamic analysis consisted of serial determination of serum analytes neopterin and β2 microglobulin 
and of messenger RNA (mRNA) expression of the interferon-inducible protein kinase (PKR) and 2’5’ 
oligoadenylate synthetase (OAS).  Neopterin, a pyrazinopyrinidine compound, is produced by macrophages 
after induction by interferons and serves as a marker of cellular immune system activation. (9)  β2 
microglobulin is a protein found on the surface of many cells, including white blood cells.  Increased production 
of white blood cells, as seen with interferon administration, causes β2 microglobulin levels in the blood to 
increase.  PKR is an interferon-inducible serine/threonine protein that is part of the innate immune response and 
inhibits viral replication.  Its mechanism of action involves RNA-dependent autophosphorylation, leading to 
inhibition of translation. (10, 11)  OAS is one of many genes encoding enzymes with antiviral activities.  It is 
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important for antiviral response, and its activity is required by cells to activate the endonuclease RNase L, 
which degrades RNA. (12).   
 
Blood for measurement of neopterin and β2 microglobulin was collected at predose, 24, 48, 72, 96, 120, and 
144 hours post dose.  Five subjects in the control interferon group had these analytes measured only at predose, 
24, 48, and 144 hours.  Blood for PKR and OAS mRNA was collected using a protease inhibitor RNALater 
(Ambion, Inc., Austin, TX) or Paxgene collection tubes (Qiagen, Valencia, CA) at predose, 8, 12, 24, 48, and 
72 hours post study drug administration.  Five subjects who received the control interferon did not have a 72-
hour sample for PKR or OAS.   
 
Pharmacokinetic Data Analysis  
Pharmacokinetic analysis was performed using WinNonLin Enterprise version 4.1 (Pharsight Inc., Mountain 
View, CA).  A non-compartmental approach was employed.  Analysis of pharmacokinetics was performed out 
to 24 hours.  Area under the curve (AUC) was determined using the linear trapezoidal rule.   A terminal 
elimination constant was determined if judged appropriate by visual examination of the terminal time points.  In 
cases where a terminal elimination could not be determined, only AUC0-24 hr, maximum concentration (Cmax), 
and time to maximum concentration (Tmax) were generated.  For those in whom a reliable terminal elimination 
constant could be determined, half life, clearance, and volume of distribution were determined.  Analysis of data 
from subjects receiving AVI-005 0.5 MIU was not performed due to concentrations below the limit of 
quantification.   
 
Statistical Methods 
Pharmacokinetics 
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AUC and Cmax values were natural log-transformed.  Means, standard deviations, minimums, maximums, and 
medians were calculated for each dose level and treatment group.  Arithmetic means were back-transformed (by 
taking anti-logs) to obtain geometric means and geometric mean ratios.  The 90% confidence intervals for 
geometric means were calculated for AVI-005 5 MIU and control interferon groups. 
 
At the 5 MIU dose level, an unequal variances t-test (with Satterthwaite degrees-of-freedom) was used to 
compare AVI-005 and control interferon for parameters AUC0-24 hr and Cmax.  Ratios (AVI-005/control 
interferon) of geometric means were calculated by back-transforming the difference of means, and a 90% 
confidence interval was calculated for this ratio.  Residuals were computed and examined for normality.  
Summary statistics (minimum, maximum, standard deviation, and median or harmonic mean) were computed 
for half-life (harmonic mean) and Tmax (median) values. 
 
Pharmacodynamics 
Pharmacodynamic analysis consisted of serial determination of serum analytes neopterin and β2 microglobulin 
and mRNA expression of PKR and OAS.  These were analyzed as fold increase from the baseline for each, with 
determination of an area under the fold increase curve and Cmax, the maximum increase from baseline.  
Geometric mean ratios of AUC0-144 hr and Cmax were compared, with 90% confidence intervals calculated for 
AVI-005 5 MIU and control interferon groups.  Measurement of neopterin and β2 microglobulin was performed 
at predose, 24, 48, 72, 96, 120, and 144 hours post dose.  One half of the subjects in the control interferon group 
had these analytes measured only at predose, 24, 48, and 144 hours.  One subject was not included in the 
analysis of neopterin and β2 microglobulin due to a very high baseline neopterin.  This subject did not have any 
evidence of viral infection at the time of dosing, but did develop some symptoms of upper respiratory tract 
infection in the subsequent 30 days, which may account for this finding.   
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Data points for neopterin and β2 microglobulin for the 120 hour time point were not available for one subject, 
and data for the 144 hour time point were not available for 4 subjects.  For this reason, both AUC0-120 hr and 
AUC0-144 hr were determined.  Examination of the geometric mean ratio between AVI-005 5 MIU and control 
interferon was performed on AUC0-144 hr and Cmax.  The AUC0-120 hr was used to compare different AVI-005 dose 
levels.   
 
PKR and OAS mRNA samples were assayed at predose, 8, 12, 24, 48, and 72 hours.  Five subjects who 
received control interferon did not have a 72 hour sample for PKR or OAS.  Examination of the geometric mean 
ratio between AVI-005 5 MIU and control interferon was performed on AUC0-72 hr and Cmax.  
 
RESULTS 
 
Pharmacokinetics 
Table 1 shows the PK parameters of the 3 measured groups.  Half life, volume of distribution and clearance for 
the AVI-005 1.66 MIU were not presented because these parameters could be estimated for only one subject of 
four receiving this treatment.  For groups receiving 5 MIU of AVI-005 or control interferon, these parameters 
were generated only in whom reliable terminal elimination phases could be determined.  Interferon 
concentrations could not be reliably quantified in one subject receiving control interferon.  This subject did, 
however, mount pharmacodynamic responses suggestive of interferon effect in all 4 analytes measured. 
 
A comparison of the pharmacokinetic parameters of AVI-005 and control interferon at the 5 MIU dose is 
presented in Table 2.  AUC0-24 hr and Cmax for the AVI-005 group was approximately 2 fold greater than in the 
control interferon group.  It should be noted that both AVI-005 and control interferon were dosed on an activity 
(MIU) basis, though analytic characterization was performed on mass of interferon.  To correct for the 
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differences in mass of interferon administered, individual subject parameters of AUC0-24 hr and Cmax were 
divided by the mass of drug administered.  Normalization of the AUC0-24 hr and Cmax data to mass of drug 
administered decreased the difference between the two treatments, although AUC0-24 hr of AVI-005 remained 
significantly larger than that of control interferon, (p=<0.001).  The 90% confidence intervals for both dose-
normalized AUC0-24 hr and Cmax extended higher than the customary upper limit pharmacokinetic geometric 
mean ratio bound of 1.25 for bioequivalence. 
 
Pharmacodynamics 
Neopterin AUC and Cmax rose with increasing administered dose of AVI-005 (Figure 1).  β2 microglobulin 
demonstrated a similar pattern of dose-dependent increase in AUC and Cmax (Figure 2).  At the 5 MIU dose, 
control interferon and AVI-005 had comparable neopterin and β2 microglobulin AUC0-144 hr and Cmax (Table 3).  
The only statistically significant finding was an increase of control interferon β2 microglobulin in Cmax.  For all 
treatment groups, there was an increase in OAS and PKR over baseline values (Figures 3 and 4).  However, 
there was no appreciable dose relationship of AVI-005 to induction of either OAS or PKR.  Control drug 
generated a larger OAS AUC0-72 hr and Cmax compared to AVI-005 5 MIU, though the confidence intervals 
around the point estimate of the geometric mean ratios was large.(Table 4)  Differences in PKR between each of 
these treatments was less, but there remained a fair amount of intersubject variability response. 
 
Safety Results 
Twenty seven of the 28 subjects reported at least 1 adverse event.  Threee subjects in the AVI-005 0.5 MIU 
group reported adverse events.  Four subjects in the AVI-005 1.66 MIU group reported adverse events.  Ten 
subjects in the AVI-005 5 MIU, as well as 10 subjects in the control interferon group reported adverse events.  
A summary of adverse events is presented in Table 5.. 
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DISCUSSION 
This study describes the first human experience with AVI-005, an avian derived, human IFN-α2b.  Unlike the 
presently commercially available IFN-α2b products, Intron A (control interferon) and PEG Intron, AVI 005 has 
glycosylation that endows the drug with a structure very similar to the endogenously produced IFN-α2b.  In this 
rising single dose phase 1 study, AVI-005 demonstrated a safety profile that was similar to that of an equivalent 
unit dose of control interferon, with no unanticipated toxicities observed. 
 
Biological markers were measured to assess the in vivo pharmacologic response to AVI-005.  Though a direct 
dose:response relationship has not always been reported, there is consensus that the markers used in this study 
demonstrate biological response to interferons. (3, 13-17).  There was an increase in the pharmacodynamic 
response markers of neopterin and β2 microglobulin to increasing doses of AVI-005, though the small number 
of subjects in the lower dose ranges and sequential dose escalation design precluded a formal assessment of 
dose response linearity.  Though AVI-005 clearly induced OAS and PKR mRNA translation, there did not 
appear to be as clear a relationship in magnitude of change from baseline to dose administered.  It should also 
be noted that the present study differs from others in the use of mRNA expression of OAS and PKR, rather than 
actual measurement of these proteins, though it can be inferred that the two should be linked.  In addition to 
measured pharmacodynamic responses, there was also a dose-related increase in adverse events, which also 
supports the biologic activity of AVI-005.  In contrast to the dose dependency of most of the pharmacodynamic 
responses, there was a lack of apparent pharmacokinetic dose response.  This is likely a function of small 
number of subjects in the AVI-005 1.66 MIU group, drug concentrations near the lower limit of quantification 
in this group and a large degree of intersubject variability. 
 
While there were no a priori equivalence or superiority hypotheses tested, pharmacokinetic and 
pharmacodynamic comparisons between AVI-005 and control interferon can be made.  The Tmax was similar for 
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both drugs, suggesting a similar rate of distribution or uptake from site of intramuscular injection, though 
formal comparisons of relative bioavailability could not be determined since administration of drug by the 
intravenous route was not performed.  At a comparable dose of control interferon on an activity basis, AVI 005 
demonstrates greater systemic exposure to mass of drug, as measured AUC0-24 hr.  This difference was 
decreased, but remained to some degree, after normalization for mass of drug administered.  AVI-005 and 
control interferon can not be considered bioequivalent by strict pharmacokinetic standards, as the 90% 
confidence intervals of the geometric mean ratios of the two drugs for AUC0-24 hr and Cmax lie outside of the 
generally accepted 0.8-1.25 bounds and the study was not conducted in a crossover design in the same 
individual.  Direct statistical comparisons of half life, volume of distribution and clearance between the two 
treatments are not appropriate due to the inability to measure a terminal elimination phase in a number of 
individuals, as described earlier.  However, it can be hypothesized that the more glycosylated conjugation of 
AVI-005 probably does not confer the increase in half life bestowed by polyethylene glycol conjugation, as 
seen with PEG-Intron.  
 
There were no protocol-specified a priori pharmacodynamic bounds to compare AVI-005 and control 
interferon.  However, using bioequivalence bounds of 0.5-2.0 for the geometric mean ratio between the two 
drugs, there did appear to be a comparable response in the markers of neopterin and β2 microglobulin.  For the 
pharmacodynamic markers of OAS transcription, control interferon generated a larger response than AVI-005, 
while the opposite was true for PKR.  However, it should be noted that the intersubject variability for OAS and 
PKR were large, making any firm conclusion about the relative potency of each drug on these markers difficult.  
In addition, the sensitivity of these markers to discriminate relative biologic potency, nor the validity of these 
markers as surrogate endpoints for clinical efficacy, have not been definitively established  
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In conclusion, a similar dose of the avian- produced human IFN-α2b AVI-005 generates a larger AUC0-24hr   
than the control interferon Intron A, a commercially available recombinant interferon -α2b with years of 
clinical experience and proven efficacy.  AVI-005 has a safety profile with a single dose that appears to be 
comparable to that of control interferon, and generates a similar pharmacodynamic response when administered 
in an equipotent dose.  It is not known if the glycosylation of AVI-005 provides any advantages compared to 
non-glycosylated versions with multiple doses in patients with interferon-remediable disease.  Given the 
potential reduced cost of production of this product compared to standard interferons, AVI-005 may expand the 
use of IFN-α2b to populations in the world whom at the present time do not have access to this product. 
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Table 1.  Summary of Mean Values of Each of the Treatment Groups 
  
AVI-005  
1.66 MIU 
AVI-005  
5 MIU 
Control Interferon 
 5 MIU 
Parameter Unit Mean SD Mean SD Mean SD 
Half life hr NDd NDe 7.1 b 2.0 6.1 c 2.4 
Tmax hr 10a NA 5a NA 7a NA 
Cmax pg/mL 239 124 237 93.5 122 52 
AUC0-24 hr hr*pg/mL 3000 1810 2720 1250 1090 321 
Volume of 
Distribution  L NDd NDe 114 b 43 154 c 55 
Clearance L/hr NDd NDe 12 b 6 18 c 5 
a
 Median 
b
 Determined from 6 individuals 
c
 Determined from 5 individuals 
d
 Half life, Volume of Distribution and Clearance were not presented because these parameters could be 
estimated for only one subject of four receiving this treatment 
e
 Missing data 
NA= non-applicable 
ND= not done
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Table 2. Geometric Mean Ratios of AVI-005 5 MIU and Control Interferon and Geometric Mean Ratios 
Normalized to Mass of Drug Administered (AUC0-24 hr and Cmax) 
   
   
  
Geometric Means 
AVI-005 Control 
interferon 
 Parameter Units 
(N = 10) (N = 9) 
 
Ratio of Geometric 
Means (AVI-005/ 
Control Interferon) and 90% 
Confidence Interval 
AUC0-24 hr hr•pg/mL 2,510 1,050 2.37 (1.80, 3.13) 
Cmax pg/mL 220 114 1.94 (1.42, 2.66) 
Tmax † hr 5.00 7.00  
AUC0-24 hr dM hr•pg/mL/ug 80 55 1.46 (1.10, 1.93) 
CmaxdM pg/mL/ug 7 6 1.19 (0.87, 1.63) 
†
 Median 
dM = normalized to mass of drug administered 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patel    AVI-005 (IFN-α2b) in healthy volunteers 
 
17 
 
 
Table 3. Fold Increase in β2 Microglobulin Following AVI-005 5 MIU or Control Interferon 
 
Geometric Means 
AVI-005 Control 
Interferon  
 
 Parameter 
 (units) 
 
Pharmacodynamic 
Marker 
(N = 10) (N = 5) 
 
Ratio of Geometric 
 Means (AVI-005/ 
Control Interferon) and 90% 
 Confidence Interval 
AUC0-144 hr (fold increase-hr) β2 microglobulin     180     200   0.92 (0.84, 1.00)     
Cmax (fold increase)                 β2 microglobulin       1.6       2.0   0.81 (0.71, 0.91)     
AUC0-144 hr (fold increase-hr)          Neopterin     370     402   0.92 (0.67, 1.27)     
Cmax (fold increase)                 Neopterin       4       5   0.87 (0.65, 1.18)     
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Table 4.  Fold Induction for PKR and OAS Following AVI-005 5 MIU or Control Interferon  
       
     Geometric Means 
   AVI-005 Control 
Interferon 
 
Parameter 
(units) 
(N = 10) (N = 5) 
 
Ratio of Geometric 
Means (AVI-005/ 
Control Interferon) and 90% 
Confidence Interval 
OAS AUC0-72 hr  
(fold increase-hr) 
    570     866   0.66 (0.32, 1.35)     
 Cmax  
(fold increase) 
     25      34   0.73 (0.34, 1.58)     
PKR AUC0-72 hr  
(fold increase-hr) 
    397     344   1.15 (0.68, 1.96)     
 Cmax  
(fold increase) 
     21      16   1.27 (0.67, 2.44)     
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Table 5.  Number of Subjects with Most Common Adverse Events 
 AVI-005 
0.5 MIU 
N = 4 
AVI-
005 
1.66 
MIU 
N = 4 
AVI-
005 
5.0 MIU 
N = 10 
Control 
Interferon 
5.0 MIU 
N = 10 
Total Subjects with Adverse 
Eventsa 
3 4 10 10 
Adverse Event b     
Pyrexia 0 0 9 10 
Headache 2 3 8 8 
Chills 0 0 7 8 
Myalgia 0 1 3 2 
Nausea 0 1 2 0 
Pharyngolaryngeal pain 1 0 2 0 
Pain in extremity 0 1 1 1 
Back pain 0 1 0 2 
Average Number of Adverse 
Events per Subjectc 
0.75 1.75 3.20 3.10 
a
 Includes subjects experiencing at least one of the most common adverse events (>10% of all subjects). 
b
 Multiple occurrences of the same adverse event within a subject are counted once. 
c
 Average is generated by dividing the total number of adverse events in a group by the number of subjects in 
the respective group. 
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  Figure 1: Neopterin (% change from baseline) 
Patel    AVI-005 (IFN-α2b) in healthy volunteers 
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Figure 2: β2 Microglobulin (% change from baseline) 
Patel    AVI-005 (IFN-α2b) in healthy volunteers 
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Figure 3: 2’5’ oligoadenylate synthetase (% change from baseline) 
Patel    AVI-005 (IFN-α2b) in healthy volunteers 
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Figure 4: Interferon-inducible protein kinase (% change from baseline) 
Patel    AVI-005 (IFN-α2b) in healthy volunteers 
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